bpc 157 effects risks BPC-157 for athletes and injury treatment: Science, safety, and legal concerns bpc-157 human clinical trials safety
Description
Human studies are yet to unpack BPC-157s potential benefits
Since the first commercial success of human insulin (Humulin) in 1982, over 80 BAPPs have been approved and administered worldwide in clinics, with more than 150 candidates currently undergoing clinical development and an additional 400 600 candidates in preclinical studies [8]
The enemy is the model
However, Instead of a single change point, they reported three slopes resulting in two change points and three subgroups
